Japan’s Shionogi Seen Defending Self Against Takeover With Sciele Buy
This article was originally published in PharmAsia News
The acquisition by Japan's Shionogi of U.S. drug maker Sciele Pharma is seen as an attempt to protect itself from being an acquisition target because of its attractive drug pipeline. Isao Teshirogi, Shionogi president, emphasizes the firm's acquisition of a U.S. sales network, but the firm had resisted that move in the past. The company may have changed its attitude when it began to see progress in developing new drug candidates to treat major problems such as obesity and HIV raising its profile and making it a takeover target in the eyes of Western drug makers. (Click here for more - a subscription may be required
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.